JP2022537685A5 - - Google Patents

Info

Publication number
JP2022537685A5
JP2022537685A5 JP2021573428A JP2021573428A JP2022537685A5 JP 2022537685 A5 JP2022537685 A5 JP 2022537685A5 JP 2021573428 A JP2021573428 A JP 2021573428A JP 2021573428 A JP2021573428 A JP 2021573428A JP 2022537685 A5 JP2022537685 A5 JP 2022537685A5
Authority
JP
Japan
Prior art keywords
composition according
composition
calcium alpha
ketoglutaric acid
controlled
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021573428A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022537685A (ja
JP7751291B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/036987 external-priority patent/WO2020252014A1/en
Publication of JP2022537685A publication Critical patent/JP2022537685A/ja
Publication of JP2022537685A5 publication Critical patent/JP2022537685A5/ja
Priority to JP2025080904A priority Critical patent/JP2025124683A/ja
Application granted granted Critical
Publication of JP7751291B2 publication Critical patent/JP7751291B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021573428A 2019-06-10 2020-06-10 アルファ－ケトグルタル酸塩の持続放出組成物 Active JP7751291B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025080904A JP2025124683A (ja) 2019-06-10 2025-05-14 アルファ－ケトグルタル酸塩の持続放出組成物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962859595P 2019-06-10 2019-06-10
US62/859,595 2019-06-10
US201962929024P 2019-10-31 2019-10-31
US62/929,024 2019-10-31
PCT/US2020/036987 WO2020252014A1 (en) 2019-06-10 2020-06-10 Sustained-release compositions of alpha-ketoglutarate

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025080904A Division JP2025124683A (ja) 2019-06-10 2025-05-14 アルファ－ケトグルタル酸塩の持続放出組成物

Publications (3)

Publication Number Publication Date
JP2022537685A JP2022537685A (ja) 2022-08-29
JP2022537685A5 true JP2022537685A5 (https=) 2023-06-16
JP7751291B2 JP7751291B2 (ja) 2025-10-08

Family

ID=73781275

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021573428A Active JP7751291B2 (ja) 2019-06-10 2020-06-10 アルファ－ケトグルタル酸塩の持続放出組成物
JP2025080904A Pending JP2025124683A (ja) 2019-06-10 2025-05-14 アルファ－ケトグルタル酸塩の持続放出組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025080904A Pending JP2025124683A (ja) 2019-06-10 2025-05-14 アルファ－ケトグルタル酸塩の持続放出組成物

Country Status (12)

Country Link
US (1) US20220265586A1 (https=)
EP (1) EP3980001B1 (https=)
JP (2) JP7751291B2 (https=)
KR (1) KR20220044478A (https=)
CN (1) CN114126601B (https=)
AU (1) AU2020292278B2 (https=)
BR (1) BR112021024952A2 (https=)
DK (1) DK3980001T3 (https=)
ES (1) ES3054304T3 (https=)
IL (1) IL288782B1 (https=)
TW (1) TWI869410B (https=)
WO (1) WO2020252014A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102833111B1 (ko) * 2018-09-25 2025-07-10 폰세 드 리온 헬스 데지그네이티드 액티비티 컴퍼니 칼슘 알파-케토글루타레이트의 제조 방법
MX2024008182A (es) * 2021-12-29 2024-09-24 Jrs Pharma Gmbh & Co Kg Lubricante para productos farmacéuticos y nutracéuticos.
WO2024123738A1 (en) * 2022-12-06 2024-06-13 Ponce De Leon Health Designated Activity Company Compositions and methods for treating diseases responsive to akg-vitamin b coadministration

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4389393A (en) * 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US6905707B2 (en) * 1998-05-28 2005-06-14 Medical Research Institute Controlled release arginine alpha ketoglutarate
US8293277B2 (en) * 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
CO5140079A1 (es) * 1998-10-14 2002-03-22 Novartis Ag Composicion farmaceutica de liberacion sostenida y metodo para liberar un agente farmaceuticamente activo de liberacion sostenida y metodo para liberar un agente far- maceuticamente activo
EP1512403A1 (en) * 1999-12-03 2005-03-09 Polichem S.A. Methods for making sustained-release pharmaceutical compositions of ergot alkaloids having improved bioavailability and compositions thereof
AU2002228955B2 (en) * 2000-12-20 2005-09-29 Alcon Inc. Solution for removing cataracts via liquefracture
US20060029668A1 (en) * 2002-10-24 2006-02-09 Ron Eyal S Sustained release L-arginine formulations and methods of manufacture and use
EP1778616A1 (en) * 2004-08-09 2007-05-02 Cancer Research Technology Limited Alpha-ketoglutarates and their use as therapeutic agents
FR2967578B1 (fr) * 2010-11-18 2012-12-28 Advicenne Pharma Composition pharmaceutique comportant des sels de citrate et de bicarbonate, et son utilisation pour le traitement de la cystinurie
ITBO20120226A1 (it) * 2012-04-24 2013-10-25 Alfa Wassermann Spa Composizioni comprendenti ornitina alfa-chetoglutarato, processi per il loro ottenimento e il loro uso.
US11331287B2 (en) * 2013-06-06 2022-05-17 Balchem Corporation Iron supplement
ITFI20130184A1 (it) * 2013-08-01 2015-02-02 Valpharma Internat S P A Una formulazione farmaceutica di gliclazide a rilascio modificato, somministrabile per via orale, e suo metodo di produzione.
CN108721242B (zh) * 2015-06-03 2021-03-02 南京三迭纪医药科技有限公司 药品剂型及其使用
EP3518915A4 (en) * 2016-09-30 2020-04-15 The Regents of the University of California ALPHA KETOBUTYRATE, ALPHA KETOGLUTARATE AND 2-HYDROXYBUTYRATE FOR STIMULATING HAIR GROWTH
KR20180062063A (ko) * 2016-11-30 2018-06-08 (주) 메티메디제약 서방형 항암용 약학 조성물
MX2017004010A (es) * 2017-03-27 2018-02-09 Antonio Hernandez Miramontes Jorge Mezcla de oxalacetato, alfacetoglutarato, ácido tartánico y sales de lactato de calcio y sodio, para tratar pacientes con insuficiencia renal crónica.
SG10202107237SA (en) * 2017-04-25 2021-08-30 Buck Inst Res Aging Formulations for extending lifespan and healthspan

Similar Documents

Publication Publication Date Title
JP2021155415A5 (https=)
JP2022537685A5 (https=)
CA2749903C (en) Solid pharmaceutical composition comprising amlodipine and losartan and process for producing same
JP2021512117A5 (https=)
JP2021519288A5 (https=)
US20030152628A1 (en) Dual release formulation comprising levodopa ethyl ester and a decarboxylase inhibitor in an immediate-release layer with levodopa ethyl ester in a controlled release core
TWI750143B (zh) 含有2-{4-[n-(5,6-二苯基吡-2-基)-n-異丙基胺基]丁基氧基}-n-(甲基磺醯基)乙醯胺之醫藥組合物
JP2010518122A5 (https=)
JP2015091822A5 (https=)
CN102170870A (zh) 恩他卡朋或其盐的缓释药物组合物
JPH06500313A (ja) 動物及び人間の疼痛及び／又は炎症の抑制時における薬剤ならびにその製造及びその使用
WO2015156581A1 (ko) 안정성이 개선된 프레가발린을 함유하는 약제학적 조성물 및 이의 제조방법
JP2006505558A (ja) イブプロフェンナトリウムの剤形
JP2020523335A5 (https=)
WO2003005967A2 (en) Dual release levodopa ethyl ester and decarboxylase in controlled release core
JP2024083460A5 (https=)
JP2022532766A5 (https=)
JP2015518038A5 (https=)
JP5211040B2 (ja) ピリジルメチルスルフィニルベンズイミダゾールのための経口速放医薬製剤
ES2668379T3 (es) Método para el tratamiento de trastornos del movimiento con befiradol
US20050203115A1 (en) Narcotic-NSAID ion pairs
EP0901372B1 (en) Potassium, sodium and tris oxaprozin salt pharmaceutical formulations
CN111635315A (zh) 一种解热镇痛药物及其制备方法和应用
CN116036079B (zh) 一种复合物的药物组合物及其制备方法
CN107018650B (zh) 包含氨氯地平和氯沙坦的固体药物组合物